| Literature DB >> 33229341 |
Wenzheng Guo1,2, Kaimi Li1,3, Beibei Sun4, Dongliang Xu1,5, Lingfeng Tong5, Huijing Yin1, Yueling Liao1,5, Hongyong Song1,5, Tong Wang1,5, Bo Jing1,5, Min Hu1,5, Shuli Liu6, Yanbin Kuang7, Jing Ling8, Qi Li8, Yadi Wu9, Qi Wang7, Feng Yao10, Binhua P Zhou9, Shu-Hai Lin11, Jiong Deng12,4,5.
Abstract
Cancer cells need to generate large amounts of glutathione (GSH) to buffer oxidative stress during tumor development. A rate-limiting step for GSH biosynthesis is cystine uptake via a cystine/glutamate antiporter Xc-. Xc- is a sodium-independent antiporter passively driven by concentration gradients from extracellular cystine and intracellular glutamate across the cell membrane. Increased uptake of cystine via Xc- in cancer cells increases the level of extracellular glutamate, which would subsequently restrain cystine uptake via Xc-. Cancer cells must therefore evolve a mechanism to overcome this negative feedback regulation. In this study, we report that glutamate transporters, in particular SLC1A1, are tightly intertwined with cystine uptake and GSH biosynthesis in lung cancer cells. Dysregulated SLC1A1, a sodium-dependent glutamate carrier, actively recycled extracellular glutamate into cells, which enhanced the efficiency of cystine uptake via Xc- and GSH biosynthesis as measured by stable isotope-assisted metabolomics. Conversely, depletion of glutamate transporter SLC1A1 increased extracellular glutamate, which inhibited cystine uptake, blocked GSH synthesis, and induced oxidative stress-mediated cell death or growth inhibition. Moreover, glutamate transporters were frequently upregulated in tissue samples of patients with non-small cell lung cancer. Taken together, active uptake of glutamate via SLC1A1 propels cystine uptake via Xc- for GSH biosynthesis in lung tumorigenesis. SIGNIFICANCE: Cellular GSH in cancer cells is not only determined by upregulated Xc- but also by dysregulated glutamate transporters, which provide additional targets for therapeutic intervention. ©2020 American Association for Cancer Research.Entities:
Year: 2020 PMID: 33229341 DOI: 10.1158/0008-5472.CAN-20-0617
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701